According to MarketsandMarkets™, the fungicides market is estimated at USD 26.87 billion in 2026 and is projected to reach ...

Bioinsecticide innovator advances lead aphid product toward regulatory approval, demonstrating technology resilience under ...

19 October 2026, São Paulo: Dutch biologicals company Koppert has launched Macan, a biological foliar fungicide, for the ...

INmune Bio Inc. and Quantum Computing Inc. partner to explore how AI and quantum computing can advance Alzheimer’s drug research. INmune Bio Inc. and Quantum Computing Inc. Boca Raton, Florida, ...

INmune Bio Inc. and Quantum Computing Inc. today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks ...

First regulatory approval enables Phytalix’s 2026/27 commercial launch in Brazil, bringing a new biological mode of action and the first commercial ascaroside to the world’s leading market for ...

San Francisco, California — [September 25, 2026] — MarWell Bio Inc. today announced that it has been awarded a research contract under the Defense Advanced Research Projects Agency's (DARPA) [Network ...

RESEARCH TRIANGLE PARK, N.C. & THE WOODLANDS, Texas--(BUSINESS WIRE)--Kincell Bio and Cellipont Bioservices today announced the completion of their merger to form Kincellis Advanced Therapies ...

Two newly published studies from Trinity College Dublin scientists raise significant concerns about the use of agricultural fungicides.That is because they show fungicides can rapidly drive soil ...

Companies combine Modalis' CRISPR-GNDM® epigenome editing platform with Exegenesis Bio's EMC181 muscle-tropic AAV capsid to pursue a mutation-agnostic DMD therapy Exegenesis Bio and Modalis ...